Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Bolzano – page 4

83 clinical trials in Bolzano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Bolzano at a glance
83
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

83 trials in Bolzano

Open in trial search

Lung cancer metastatic

Not yet recruiting

Study of Drug Combination with Pembrolizumab Guided by Blood Biomarkers for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

K-ras gene mutation+2

Not yet recruiting

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:F. Hoffmann-La Roche AG

Chronic prostatitis/chronic pelvic pain syndrome

Not yet recruiting

Study on Botulinum Toxin Type A for Adults with Chronic Pelvic Pain Syndrome (CPPS)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A
  • Sponsor:Ospedale San Raffaele S.r.l.

Eosinophilic granulomatosis with polyangiitis

Not yet recruiting

Study on the Effectiveness of Tezepelumab for Adults with Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Imperial College London Limited

Acute respiratory distress syndrome

Not yet recruiting

Study on Pirfenidone for Preventing Lung Fibrosis in Patients with Acute Respiratory Distress Syndrome (ARDS)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Ospedale San Raffaele S.r.l.

Prostate cancer

Not yet recruiting

Study on Prostate Cancer: Comparing Stereotactic Body Radiation Therapy Alone or with Triptorelin and Bicalutamide for Patients with Acinar Cell Prostatic Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bicalutamide
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Genitourinary tract neoplasm

Not yet recruiting

Study on Niraparib for Patients with Advanced Urothelial Cancer After Initial Platinum Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Universita' Degli Studi Di Torino

Colon cancer stage III+1

Not yet recruiting

Study on Post-Surgery Treatment for Colon Cancer Patients Using Trifluridine, Irinotecan, and Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fondazione GONO G.I.

Lung carcinoma cell type unspecified recurrent

Not yet recruiting

Study of Durvalumab with Thoracic Radiotherapy and Chemotherapy for Patients with Extensive Stage Small Cell Lung Cancer After Initial Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Azienda Ospedaliero Universitaria Di Modena

IgA nephropathy

Not yet recruiting

Study on Corticosteroids, Dapagliflozin, and Drug Combination for Proteinuria in IgA Nephropathy Patients with Active or Chronic Kidney Lesions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Fondazione Schena Centro Europeo Della Ricerca Sulle Malattie Renali

Hormone-refractory prostate cancer+1

Not recruiting

Study of Vobramitamab Duocarmazine and Prednisone for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Macrogenics Inc.

Colitis ulcerative

Not recruiting

Study on the Effects of Eclitasertib in Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Bolzano

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking research focusing on various blood cancers, including Multiple Myeloma and Acute Lymphoblastic Leukemia. Studies evaluate innovative treatment combinations and novel therapeutic approaches.

  • Multiple Myeloma Treatment Strategies
  • Leukemia Therapy Optimization
  • Stem Cell Transplantation

Several trials are investigating targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Solid Tumors

Comprehensive research into various solid cancers, including breast cancer, prostate cancer, and head and neck malignancies. Studies focus on targeted therapies and novel treatment combinations.

  • Advanced Breast Cancer Treatments
  • Colorectal Cancer Therapy
  • Bladder Cancer Management

Trials explore personalized medicine approaches based on genetic markers and innovative drug combinations.

03 Autoimmune Conditions

Clinical investigations of Polymyalgia Rheumatica and other autoimmune disorders, evaluating new biological treatments and therapeutic strategies.

  • Inflammatory Disease Management
  • Novel Biological Therapies
  • Long-term Treatment Safety

Research focuses on improving treatment outcomes while minimizing steroid dependency.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.